Volume 11, Issue 8 (11-2013)                   IJRM 2013, 11(8): 665-0 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nadjarzadeh A, Dehghani Firouzabadi R, Vaziri N, Daneshbodi H, Lotfi M H, Mozaffari-Khosravi H. The effect of omega-3 supplementation on androgen profile and menstrual status in women with polycystic ovary syndrome: A randomized clinical trial. IJRM 2013; 11 (8) :665-0
URL: http://ijrm.ir/article-1-448-en.html
The effect of omega-3 supplementation on androgen profile and menstrual status in women with polycystic ovary syndrome: A randomized clinical trial
Azadeh Nadjarzadeh1 , Razieh Dehghani Firouzabadi2 , Niloofar Vaziri * 3, Hoorieh Daneshbodi4 , Mohammad Hassan Lotfi5 , Hassan Mozaffari-Khosravi1
1- Department of Nutrition, Faculty of Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2- Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3- International Campus of Shahid Sadoughi University of Medical Sciences, Yazd, Iran , niloofar_vzr@ssu.ac.ir
4- International Campus of Shahid Sadoughi University of Medical Sciences, Yazd, Iran
5- Department of Biostatistics and Epidemiology, Faculty of Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Abstract:   (4793 Views)
Background: There is some evidence regarding the effect of poly unsaturated fatty acid intake on androgen levels and gonadal function in polycystic ovary syndrome (PCOS).
Objective: This study was conducted to determine the effect of omega-3 supplementation on sex hormone-binding protein (SHBG), testosterone, free androgen index (FAI) and menstrual status in women with PCOS.
Materials and Methods: This double-blind randomized clinical trial was conducted on 78 overweight/obese women with PCOS. Participants were randomized to receive omega-3 (3gr/day) or placebo for 8 weeks. Data about weight, height and nutrient intake as well as blood samples were collected before and after intervention. Serum concentrations of testosterone (nmol/L) and SHBG (nmol/L) were measured. FAI was also calculated as the ratio of testosterone to SHBG.
Results: Seventy eight patients (age: 26.92±5.46 yrs, Body Mass Index: 31.69±4.84 Kg/m2) completed the study. There was no significant difference in mean age, weight, height, Body Mass Index and intake of energy, and macronutrients between 2 study groups before and after treatment. All the participants had irregular periods. After the trial the percentage of regular menstruation in the omega-3 group was more than the placebo group (47.2% vs. 22.9%, p=0.049). Furthermore, testosterone concentration was significantly lower in the omega-3 group compared with placebo, after supplementation (p=0.04). SHBG and FAI did not change in either group.
Conclusion: Omega-3 supplementation could reduce serum concentrations of testosterone and regulate menstrual cycle without significant effect on SHBG and FAI. Future studies with longer period of supplementation are warranted.
Keywords: Polycystic ovary syndrome, Sex hormone, Binding globulin, Omega-3.
Full-Text [PDF 461 kb]   (663 Downloads) |   |   Full-Text (HTML)  (368 Views)  
Type of Study: Original Article |
References
1. Orio F, Vuolo L, Palomba S, Lombardi G, Colao A. Metabolic and cardiovascular consequences of polycystic ovary syndrome. Minerva Ginecol 2008; 60: 39-51.
2. Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 2006; 91: 781-785. [DOI:10.1210/jc.2005-2153]
3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25. [DOI:10.1016/j.fertnstert.2003.10.004]
4. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-2749. [DOI:10.1210/jc.2003-032046]
5. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078-3082. [DOI:10.1210/jc.83.9.3078]
6. Pasquali R, Stener-Victorin E, Yildiz BO, Duleba AJ, Hoeger K, Mason H, et al. PCOS Forum: research in polycystic ovary syndrome today and tomorrow. Clin Endocrinol (Oxf) 2011; 74: 424-233. [DOI:10.1111/j.1365-2265.2010.03956.x]
7. Arslanian SA, Witchel SF. Polycystic ovary syndrome in adolescents: is there an epidemic? Current Opinion in Endocrinology. Curr Opin Endocrinol Diabetes Obes 2002; 9: 32-42. [DOI:10.1097/00060793-200202000-00006]
8. Korhonen S, Hippelainen M, iskanen L, Vanhala M, Saarikoski S. Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study. Am J Obstet Gynecol 2001; 184: 289-296. [DOI:10.1067/mob.2001.109596]
9. Jeffrey Chang R, Coffler MS. Polycystic ovary syndrome: early detection in the adolescent. Clin Obstet Gynecol 2007; 50: 178-187. [DOI:10.1097/GRF.0b013e31802f50fc]
10. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011; 7: 219-231. [DOI:10.1038/nrendo.2010.217]
11. Macut D, Panidis D, Glisic B, Spanos N, Petakov M, Bjekic J, et al. Lipid and lipoprotein profile in women with polycystic ovary syndrome. Can J Physiol Pharmacol 2008; 86: 199-204. [DOI:10.1139/Y08-014]
12. Kasim-Karakas SE, Almario RU, Gregory L, Wong R, Todd H, Lasley BL, et al. Metabolic and endocrine effects of a polyunsaturated fatty acid-richdiet in polycysticovary syndrome. J Clin Endocrinol Metab 2004; 89: 615-620. [DOI:10.1210/jc.2003-030666]
13. Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 2008; 93: 470-476. [DOI:10.1210/jc.2007-1756]
14. Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, et al. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod 2009; 24: 2286-2292. [DOI:10.1093/humrep/dep121]
15. Browning LM, Krebs JD, Moore CS, Mishra GD, O'Connell MA, Jebb SA, et al. The impact of long chain n-3 polyunsaturated fattyacid supplementation on inflammation, insulin sensitivity and CVD risk in a group of overweight women with an inflammatory phenotype. Diabetes Obes Metab 2007; 9: 70-80. [DOI:10.1111/j.1463-1326.2006.00576.x]
16. Murakami K, Sasaki S, Takahashi Y, Uenishi K, Yamasaki M, Hayabuchi H, et al. Total n-3 polyunsaturated fatty acid intake is inversely associated with serum C-reactive protein in young Japanese women. Nutr Res 2008; 28: 309-314. [DOI:10.1016/j.nutres.2008.03.008]
17. Caron MF, White CM. Evaluation of the antihyperlipidemic properties of dietary supplements. Pharmacotherapy 2001; 21: 481-487. [DOI:10.1592/phco.21.5.481.34499]
18. Demirel F, Bideci A, Cinaz P, Camurdan MO, Biberoglu G, Yesilkaya E, et al. Serum leptin, oxidized low density lipoproteinand plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007; 67: 129-134. [DOI:10.1111/j.1365-2265.2007.02849.x]
19. Rissanen T, Voutilainen S, Nyyssonen K, Lakka TA, Salonen JT. Fish oil-derived fatty acids, docosahexaenoic acid and docosapentaenoic acid, and the risk of acute coronary events: the Kuopio ischaemic heart disease risk factor study. Circulation 2000; 102: 2677-2679. [DOI:10.1161/01.CIR.102.22.2677]
20. Harper CR, Jacobson TA. The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease. Arch Intern Med 2001; 161: 2185-2192. [DOI:10.1001/archinte.161.18.2185]
21. Allahbadia GN, Merchant R. Polycystic ovary syndrome and impact on health. Mid East Fertil Soc J 2011; 16: 19-37. [DOI:10.1016/j.mefs.2010.10.002]
22. Phelan N, O'Connor A, Kyaw Tun T, Correia N, Boran G, Roche HM, et al. Hormonal and metabolic effects of polyunsaturated fatty acids in young women with polycystic ovary syndrome: results from a cross-sectional analysisand a randomized, placebo-controlled, crossover trial. Am J Clin Nutr 2011; 93: 652-662. [DOI:10.3945/ajcn.110.005538]
23. Akinsete JA, Ion G, Witte TR, Hardman WE. Consumption of high ω-3 fatty acid diet suppressed prostate tumorigenesis in C3 (1) Tag mice. Carcinogenesis 2012; 33: 140-148. [DOI:10.1093/carcin/bgr238]
24. Mohamadin AM, Habib FA, Al-Saggaf AA. Cardiovascular disease markers in women with polycystic ovary syndrome with emphasis on asymmetric dimethylarginine and homocysteine. Ann Saudi Med 2010; 30: 278-283. [DOI:10.4103/0256-4947.65255]
25. Cussons AJ, Watts GF, Mori TA, Stuckey BG. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab 2009; 94: 3842-3848. [DOI:10.1210/jc.2009-0870]
26. Kuzmanov AP. Do omega-3 fatty acids affect hormones related to polycystic ovary syndrome infertility? [M.Sc. Thesis]. United States, UMI:University of Wyoming; 2009.
27. Nestel PJ. Fish oil and cardiovascular disease: lipids and arterial function. Am J Clin Nutr 2000; 71 (suppl.): 228-231. [DOI:10.1093/ajcn/71.1.228S]
28. Marshall K. Polycystic ovary syndrome: clinical considerations. Altern Med Rev 2001; 6: 272-292.
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb